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Tyrosine hydroxylaseAbstract Toxic insults lead to increased a-synuclein expression in dopaminergic neurons. How-
ever, little information is known about a-synuclein alterations in relation to tyrosine hydroxylase
(TH) changes in locus coeruleus (LC) of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)
rat model for Parkinson’s disease (PD). Four injections (15 mg/kg each) of the neurotoxicant
MPTP to rats led to an upregulation of a-synuclein level and increased immunoreactivity with
aggregated protein in the MPTP-treated group as revealed by Western blotting and immunohisto-
chemical techniques. Meanwhile, MPTP reduced the level of and caused immunoreactivity toward
TH antibody in LC and adjoining noradrenergic neurons. These data indicate that MPTP can
induce a-synuclein alterations in other brain regions that have been implicated in the pathogenesis
of PD. The findings are also consistent with a pattern that a-synuclein modification influences the
TH level.
 2015 The Egyptian German Society for Zoology. Production and hosting by Elsevier B.V. This is an
open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).Introduction
Parkinson’s disease (PD) is a neurodegenerative disease that is
accompanied by a group of motor and non-motor symptoms
(Fathy and Addelkader, 2015). It was believed that motor
manifestations, characterized by bradykinesia, tremor, rigidity,
and postural instability, are principally attributable to degen-
eration of dopaminergic cells and decreased dopamine level
in the substantia nigra (SN) region (Masilamoni et al., 2011;
Taylor et al., 2014). Dopamine depletion can be assessed bymeasuring the level of tyrosine hydroxylase (TH), the rate
limiting enzyme for dopamine and noradrenaline (Oaks and
Sidhu, 2011). Brain tissue examination revealed reduction of
the midbrain dopamine cells and formation of Lewy bodies
(LBs); protein aggregates that include various constituents
mainly consist of a-synuclein (McCormack et al., 2008). Usu-
ally, parkinsonian manifestation is preceded by a preclinical
stage that is characterized by a group of symptoms such as
sleep disorder (Remy et al., 2005) and cognitive disturbances
(Zweig et al., 1993). The previously mentioned non-motor
symptoms were reported to be ascribed to degeneration of
brain regions other than midbrain and due to the disturbances
of neurotransmission in non-dopaminergic systems (Isaias
et al., 2011; Taylor et al., 2014).
Figure 1 Western blot analysis for TH protein level in pons. The
densitometry of TH bands was first normalized to the loading
control b-actin. The relative density of the expressions of TH in
the MPTP-treated rats relative to that in the saline-treated rats
was then calculated. The scanned image of Western blot was
analyzed with the software Image J. Data were presented as mean
± SEM. P< 0.05, MPTP-treated group versus saline-treated
group.
Figure 2 Western blot analysis for a-synuclein protein level in
pons. The densitometry of a-synuclein bands was first normalized
to the loading control b-actin. The relative density of the
expressions of a-synuclein in the MPTP-treated rats relative to
that in the saline-treated rats was then calculated. The scanned
image of Western blot was analyzed with the software Image J.
Data were presented as mean ± SEM. P< 0.05, MPTP-treated
group versus saline-treated group.
54 S.M. FathyLocus coeruleus (LC) is a pontine nucleus that was proved to
be involved in PD (Isaias et al., 2011). It has been reported that
LC is among brain regions that exhibit neuronal degeneration
in PD and it encloses projecting neurons controlling the
dopaminergic effect of SN. Furthermore, degeneration of LC
was postulated to be conjugated with the above mentioned
non-motor impairments in PD patients (Isaias et al., 2011).
a-Synuclein is a major protein of the synuclein family of
proteins that has been associated with various neurodegenera-
tive diseases such as PD, Alzheimer’s disease (AL), and multi-
ple system atrophy (MSA) (McCormack et al., 2008; Oaks and
Sidhu, 2011). Lewy bodies and Lewy neuritis are interneuronal
inclusions that are recognized in PD and consist of various
components, largely including a-synuclein (McCormack
et al., 2008). Various evidences supported the link between dis-
turbances of a-synuclein and PD pathology in animal models
(McCormack et al., 2008).
Information on the LC in PD is largely dependent on post-
mortem examination of histopathological specimens, while its
in vivo neuronal changes are largely uncovered. Despite the
fact that many studies demonstrated a-synuclein overexpres-
sion in the midbrain region of PD, little attention was given
to a-synuclein variations in LC region of PD models.
Subsequently, the aim of this study is to examine the changes
of a-synuclein protein in relation to TH alteration in the LC
brain area of a Parkinsonian MPTP rat model.Materials and methods
Experimental design
The current work was performed according to the Guidelines
of Animals Health Research Institute, Egypt. The study proto-
col was agreed by the Committee on the Ethics of Animals
Health Research Institute, Egypt (Permit Number 362).
Twenty-four male Wistar rats (200–250 gm) were kept in a
temperature controlled room under 12/12 h light/dark cycle
with the availability of food pellets and tap water ad libitum.
Rats were separated into two groups. The MPTP group
was injected intraperitoneally four times, at 2 h apart with
15 mg/kg MPTP (sigma; ST. Louis, MO, USA), while the
control rats were injected with physiological saline only. Rats
were sacrificed 7 days after administration of MPTP.
Western blot analysis
Quantification of TH and a-synuclein levels was carried out
according to (Caudle et al., 2006). For sample analysis, pons
regions were mechanically homogenized in the lysis buffer with
proteinase inhibitors and cytosolic fractions taken were
prepared for reducing and denaturing SDS–PAGE. Proteins
were separated on 12% gel and transferred using a Trans-
Blot Turbo transfer system (Bio-Rad, UK). Membranes were
blocked and probed with polyclonal rabbit anti-TH (Millipore,
Figure 3 TH immunoreactivity in the LC and adjacent noradrenergic cell groups (A) saline-treated, (B) MPTP-treated rats. Scale
bar = 100 lm.
Figure 4 Immunohistochemical analysis of a-synuclein in LC. (A) Saline-treated, (B) MPTP-treated rats, neuronal inclusions
immunoreactive for a-synuclein (arrows). Scale bar = 40 lm.
Changes in LC of a PD model 55AB152) or monoclonal anti-a-synuclein (Millipore, AB5038)
antibodies and visualized with HRP conjugated anti-rabbit
IgG (Bio-Rad, UK). Densitometry analysis was performed
using Image J software.
Immunohistochemical study
Tissue staining was carried out according to (Caudle et al.,
2006; Miller, 1997, 1999). Animals were perfused intracardially
with phosphate buffered saline (pH = 7.4) and then with 4%
paraformaldehyde and discarded. Afterward, they were placed
in 4% paraformaldehyde for 24 h, and finally cryoprotected in
30% sucrose for 48 h. The brains were then cut to a 30 lm
thickness using a cryostat microtome (Leica Microsystems).
Sections were incubated with either polyclonal anti-TH
(1:1000) antibody or monoclonal anti-a-synuclein (1:500)antibody overnight and then incubated in a biotinylated sec-
ondary antibody for 1 h at room temperature. Visualization
was performed using 3,30-diaminobenzidine (DAB) at room
temperature. Afterward, all sections were mounted on slides,
dehydrated, and coverslipped using DPX Mountant and sec-
tions were viewed using a light microscope (Leica). Negative
control sections were treated in the same way but in the
absence of primary antibodies.
Statistical analysis
Results are presented as mean ± standard error of the mean.
Statistical analysis was performed using an unpaired Student’s
t-test using a statistical package program (Sigma Plot version
11.0). Differences among groups were considered significant
at P< 0.05.
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The results in Fig. 1 displayed the TH levels of both MPTP
and saline treated animals. A significant decrease in the protein
level in pons of MPTP-treated rats as compared with saline-
treated group is shown (P< 0.05).
As presented in Fig. 2, immunoblot analysis of the pons
homogenate using an antibody for a-synuclein showed a sig-
nificant variation between MPTP-treated group in relation to
normal group. A highly significant increase in the level of
the a-synuclein protein in comparison with normal control
group is recorded (P< 0.05).
Fig. 3 reveals TH immunoreactivity in LC region and adja-
cent noradrenergic cell groups of both MPTP-treated and
saline-treated rats. MPTP treatment induces reduced
immunoreactivity toward TH antibody in the LC and related
A5 and A7 noradrenaline cell groups in comparison with the
saline-treated rats.
Immunohistochemical staining for a-synuclein demon-
strated widespread neuronal inclusions of a-synuclein in LC
region of the MPTP-treated rats (Fig. 4). The neuronal
inclusions’ morphology was globular similar to LBs, in
addition to the diffuse finely granular pattern of a-synuclein
immunoreactivity.
Discussion
Several studies have addressed the relationship between neu-
ronal damage and upregulation of a-synuclein in the midbrain
of PD animal models (Vila et al., 2000). In addition, other
brain regions have exhibited increased a-synuclein level in
response to toxicant induced neuronal destruction (Kiely
et al., 2013).
In the current research, MPTP treatment led to depletion of
TH and increased level of a-synuclein compared to saline treat-
ment in the LC region. The reduced level and immunoreactivity
of TH antibody, confirmed the noradrenergic neuronal degen-
eration in LC and adjoining noradrenergic areas of pons. In
accordance with our findings, Guard et al. (2008) showed
degeneration of this region in rats. In addition, it was
postulated that degeneration of noradrenergic neurons in LC
might start before and accelerate degeneration of dopaminergic
neurons in SN as LC region harbors projecting neurons that
modulate SN dopaminergic effect (Marien et al., 1993;
Fornai et al., 1995, 1997, 2007; Rommelfanger et al., 2007;
Rommelfanger and Weinshenker, 2007).
In addition, the current work showed a-synuclein upregula-
tion and accumulation in the LC of MPTP-treated group as
compared with saline-treated group. Previous studies have
confirmed the overexpression and accumulation of a-synuclein
in the dopaminergic system of different PD models
(McCormack et al., 2008). It has been reported that
a-synuclein upregulation was observed in the midbrain of PD
animal models following exposure to neurotoxins; MPTP,
Paraquat and Methamphetamine (Fornai et al., 2005; Liao
et al., 2005; Manning-Bog˘ et al., 2002). These previous
outcomes were further supported after MPTP injection in
non-human primates (McCormack et al., 2008). Furthermore,
a-synuclein aggregation was observed in brain regions other
than midbrain such as putamen and caudate nuclei as well as
hippocampus (Kiely et al., 2013). It was suggested thataugmentation of a-synuclein level is a key factor that might
contribute to the PD pathology. The latter finding was ascribed
to the interrelation between multiplication of the gene encoding
a-synuclein (SNCA), induced expression of the wild-type pro-
tein, and the appearance of familial Parkinsonism (Farrer
et al., 2004; Singleton et al., 2003).
Moreover, it was reported that a-synuclein is responsible
for TH reduction (Gira´ldez-Pe´rez et al., 2014). The outcome
of the recent work in the LC region can be explained based
on the previous postulate. For further support, it was demon-
strated that TH enzymatic activity can be controlled via direct
relation with a-synuclein (Perez et al., 2002), and that TH
expression was elevated in the retina of a-synuclein/c-synuclein
double knockout (KO) mice as compared with wild type and
single KO mice (Surgucheva et al., 2005).Conclusions
In conclusion, a better understanding of protein changes of
a-synuclein as well as TH in the LC of PD rats increases the
awareness that PD pathology is not restricted to midbrain only
but it is a widespread disease that influences other brain
regions.References
Caudle, W.M., Richardson, J.R., Delea, K.C., et al., 2006. Polychlo-
rinated biphenyl-induced reduction of dopamine transporter
expression as a precursor to Parkinson’s disease-associated
dopamine toxicity. Toxicol. Sci. 92 (2), 490–499.
Farrer, M., Kachergus, J., Forno, L., et al., 2004. Comparison of kind
reds with parkinsonism and a-synuclein genomic multiplications.
Ann. Neurol. 55, 174–179.
Fathy, S.M., Addelkader, I.Y., 2015. Effect of 1-methyl-4-phenyl-
1,2,3,6-tetrahydropyridine on phosphorylated neurofilament in
brain cortex of rat model for Parkinson’s disease. Ann. Res. Rev.
Biol. 6 (6), 409–415. Article no. ARRB.2015.100.
Fornai, F., Bassi, L., Torracca, M.T., et al., 1995. Norepinephrine loss
exacerbates methamphetamine-induced striatal dopamine depletion
in mice. Eur. J. Pharmacol. 283, 99–102.
Fornai, F., Alessandrı`, M.G., Torracca, M.T., et al., 1997. Effects of
noradrenergic lesions on MPTP/MPP+ kinetics and MPTP-
induced nigrostriatal dopamine depletions. J. Pharmacol. Exp.
Ther. 283, 100–107.
Fornai, F., Lenzi, P., Ferrucci, M., et al., 2005. Occurrence of neuronal
inclusions combined with increased nigral expression of a-synuclein
within dopaminergic neurons following treatment with ampheta-
mine derivatives in mice. Brain Res. Bull. 65, 405–413.
Fornai, F., di Poggio, A.B., Pellegrini, A., et al., 2007. Noradrenaline
in Parkinson’s disease: from disease progression to current thera-
peutics. Curr. Med. Chem. 14, 2330–2334.
Gira´ldez-Pe´rez, R.M., Antolı´n-Vallespı´n, M., Mun˜oz, M.D., et al.,
2014. Models of a-synuclein aggregation in Parkinson’s disease.
Acta Neuropathol. Commun. 2, 176.
Guard, B.P., El Mansari, M., Blier, P., 2008. Cross-talk between
dopaminergic and noradrenergic systems in the rat ventral
tegmental area, locus ceruleus, and dorsal hippocampus. Mol.
Pharmacol. 74, 1463–1475.
Isaias, I.U., Marotta, G., Pezzoli, G., et al., 2011. Enhanced
catecholamine transporter binding in the locus coeruleus of patients
with early Parkinson disease. BMC Neurol. 11, 88.
Kiely, A.P., Asi, Y.T., Kara, E., et al., 2013. a-Synucleinopathy
associated with G51D SNCA mutation: a link between Parkinson’s
Changes in LC of a PD model 57disease and multiple system atrophy? Acta Neuropathol. 125, 753–
769. http://dx.doi.org/10.1007/s00401-013-1096-7.
Liao, P.C., Kuo, Y.M., Hsu, H.C., et al., 2005. Local proteins
associated with methamphetamine-induced nigrostriatal dopamin-
ergic neurotoxicity. J. Neurochem. 95, 160–168.
Manning-Bog˘, A.B., McCormack, A.L., Li, J., et al., 2002. The
herbicide paraquat causes up-regulation and aggregation of a-
synuclein in mice. J. Biol. Chem. 277, 1641–1644.
Marien, M., Briley, M., Colpaert, F., 1993. Noradrenaline depletion
exacerbates MPTP-induced striatal dopamine loss in mice. Eur. J.
Pharmacol. 236, 487–489.
Masilamoni, G.J., Bogenpohl, J.W., Alagille, D., et al., 2011.
Metabotropic glutamate receptor 5 antagonist protects dopamin-
ergic and noradrenergic neurons from degeneration in MPTP-
treated monkeys. Brain 134, 2057–2073.
McCormack, A.L., Mak, S.K., Shenasa, M., et al., 2008. Pathological
modifications of a-synuclein in 1-methyl-4-phenyl-1,2,3,6-tetrahy-
dropyridine (MPTP)-treated squirrel monkeys. J. Neuropathol.
Exp. Neurol. 67 (8), 793–802. http://dx.doi.org/10.1097/
NEN.0b013e318180f0bd.
Miller, G.W., 1997. Immunochemical analysis of dopamine trans-
porter protein in Parkinson’s disease. Ann. Neurol. 41, 530–539.
Miller, G.W., 1999. Immunochemical analysis of vesicular monoamine
transporter (VMAT2) protein in Parkinson’s disease. Exp. Neurol.
156, 138–148.
Oaks, A.W., Sidhu, A., 2011. Synuclein modulation of monoamine
transporters. FEBS Lett. 585 (7), 1001–1006. http://dx.doi.org/
10.1016/j.febslet.2011.03.009.Perez, R.G., Waymire, J.C., Lin, E., et al., 2002. A role for alpha-
synuclein in the regulation of dopamine biosynthesis. J. Neurosci.
22 (8), 3090–3099.
Remy, P., Doder, M., Lees, A., et al., 2005. Depression in Parkinson’s
disease: loss of dopamine and noradrenaline innervation in the
limbic system. Brain 128, 1314–1322.
Rommelfanger, K.S., Weinshenker, D., 2007. Norepinephrine: the red
headed step child of Parkinson’s disease. Biochem. Pharmacol. 74,
177–190.
Rommelfanger, K.S., Edwards, G.L., Freeman, K.G., et al., 2007.
Norepinephrine loss produces more profound motordeficits than
MPTP treatment in mice. Proc. Natl. Acad. Sci. U.S.A. 104, 13804–
13809.
Singleton, A.B., Farrer, M., Johnson, J., et al., 2003. a-Synuclein locus
triplication causes Parkinson’s disease. Science 302, 841.
Surgucheva, I., Ninkina, N., Buchman, V.L., et al., 2005. Protein
aggregation in retinal cells and approaches to cell protection. Cell.
Mol. Neurobiol. 25 (6), 1051–1066.
Taylor, T.N., Potgieter, D., Anwar, S., et al., 2014. Region-specific
deficits in dopamine, but not norepinephrine, signaling in a novel
A30P a-synuclein BAC transgenic mouse. Neurobiol. Dis. 62 (100),
193–207.
Vila, M., Vukosavic, S., Jackson-Lewis, V., et al., 2000. a-Synuclein
up-regulation in substantia nigra dopaminergic neurons following
administration of the parkinsonian toxin MPTP. J. Neurochem. 74,
721–729.
Zweig, R.M., Cardillo, J.E., Cohen, M., et al., 1993. The locus ceruleus
and dementia in Parkinson’s disease. Neurology 43, 986–991.
